All Stories

  1. The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)

    Article • Leukemia & Lymphoma, July 2019, Taylor & Francis

    Dr Arianna Di Di Napoli, MARIA COX, Cristiano Tesei, Roberta Battistini

  2. The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis

    Article • Leukemia & Lymphoma, January 2019, Taylor & Francis

    stefano sacchi, Dr Tamar Tadmor, MARIA COX

  3. Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab

    Article • British Journal of Haematology, September 2018, Wiley

    MARIA COX

  4. Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study)

    Article • The Oncologist, April 2018, Alphamed Press

    MARIA COX

  5. Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit

    Article • British Journal of Haematology, November 2017, Wiley

    Professor Guido Bocci, MARIA COX

  6. The significance of serum immunoglobulin paraprotein in diffuse large B-cell lymphoma

    Article • British Journal of Haematology, August 2017, Wiley

    Dr Arianna Di Di Napoli, MARIA COX